Literature DB >> 28492125

Influence of HIV and other risk factors on tuberculosis.

Sana Mahtab1, David Coetzee.   

Abstract

BACKGROUND: Tuberculosis (TB) notification in South Africa has increased six-fold over the past two decades, mainly because of the HIV epidemic.
OBJECTIVES: To describe the sociodemographic and outcome characteristics of TB patients, and to identify risk factors associated with TB treatment outcomes stratified by HIV status.
METHODS: A cross-sectional study was used to analyse data from the Cape Town Metro East geographical service area (GSA) electronic TB register (ETR.Net), including adult patients aged ≥15 years who initiated TB treatment between 1 July 2011 and 30 June 2012.
RESULTS: TB case notification in the GSA was 922 per 100 000 population. Of the 12 672 TB patients registered, 50.5% were co-infected with HIV. The death rate in co-infected patients was 5.4% v. 2.8% in HIV-negative patients, the rate of treatment success 66.6% v. 73.5%, and the rate of unfavourable treatment outcome 28.1% v. 23.7%. The Khayelitsha subdistrict had the highest proportion of TB burden (37.0%) and co-infection (47.6%). Fourteen percent of patients had extrapulmonary TB, 65.9% of whom were co-infected with HIV. In the multivariate analysis, HIV infection (relative risk (RR) 1.2), retreatment (RR 1.4) and sputum smear microscopy not done (RR 1.4) were significantly associated with unfavourable treatment outcome. The Eastern (RR 0.9) and Northern (RR 0.7) subdistricts were less likely to have unfavourable outcomes compared with Khayelitsha. In the stratified analysis, retreatment and smear not done were significant risk factors for an unfavourable treatment outcome in both co-infected and HIV-negative patients.
CONCLUSIONS: The burdens of both TB and co-infection were high in this community, although HIV prevalence varied. Mortality was higher and treatment completion lower in co-infected patients than in those who were HIV-negative. Co-infection, previous TB treatment and smear not done were significant risk factors for an unfavourable outcome in all patients.

Entities:  

Year:  2017        PMID: 28492125     DOI: 10.7196/SAMJ.2017.v107i5.11271

Source DB:  PubMed          Journal:  S Afr Med J


  6 in total

1.  Influence of patients' living conditions on tuberculosis treatment outcomes in a South African health sub-district.

Authors:  Tombo Bongongo; Hendry Van der Heever; Doudou K Nzaumvila; Christian N S Saidiya
Journal:  S Afr Fam Pract (2004)       Date:  2020-08-25

2.  SMS nudges as a tool to reduce tuberculosis treatment delay and pretreatment loss to follow-up. A randomized controlled trial.

Authors:  Adam Wagstaff; Eddy van Doorslaer; Ronelle Burger
Journal:  PLoS One       Date:  2019-06-20       Impact factor: 3.240

Review 3.  Tuberculosis Treatment Outcome and Predictors in Africa: A Systematic Review and Meta-Analysis.

Authors:  Melese Yeshambaw Teferi; Ziad El-Khatib; Minyahil Tadesse Boltena; Azeb Tarekegn Andualem; Benedict Oppong Asamoah; Mulatu Biru; Hawult Taye Adane
Journal:  Int J Environ Res Public Health       Date:  2021-10-12       Impact factor: 4.614

4.  Perceptions of nurses on TB with HIV adherence counselling skills in a health sub-district, Cape Town: A qualitative study.

Authors:  Victoire Ticha; Million Bimerew; Deliwe R Phetlhu
Journal:  Health SA       Date:  2022-07-26

5.  Factors influencing maternal microchimerism throughout infancy and its impact on infant T cell immunity.

Authors:  Christina Balle; Blair Armistead; Agano Kiravu; Xiaochang Song; Anna-Ursula Happel; Angela A Hoffmann; Sami B Kanaan; J Lee Nelson; Clive M Gray; Heather B Jaspan; Whitney E Harrington
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

6.  Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis.

Authors:  Ninfa Marlen Chaves Torres; Jecxy Julieth Quijano Rodríguez; Pablo Sebastián Porras Andrade; María Belen Arriaga; Eduardo Martins Netto
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.